Opna Bio Announces Orphan Drug Designation Granted to OPN-2853 (Zavabresib) for the Treatment of Myelofibrosis

[#item_full_content]SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development…

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]